https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / Nippon Rinsho 2005 Sep;63 Suppl 9:483-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / Nippon Rinsho 2005 Sep;63 Suppl 9:483-92005-09-01 00:00:002019-02-15 09:00:05[Current status of hyperthermia for therapy of brain tumor]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / Hepatogastroenterology 2005 Sep-Oct;52(65):1502-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / Hepatogastroenterology 2005 Sep-Oct;52(65):1502-62005-09-01 00:00:002019-02-15 09:03:11Immune-related effects of local hyperthermia in patients with primary liver cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):505-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):505-162005-09-01 00:00:002019-02-15 09:19:57Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-23 / Blood 2005 Dec;106(13):4225-33
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-23 / Blood 2005 Dec;106(13):4225-332005-08-23 00:00:002019-02-15 08:44:44Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-18 / Vaccine 2005 Nov;23(45):5225-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-18 / Vaccine 2005 Nov;23(45):5225-302005-08-18 00:00:002005-08-18 00:00:00Antitumor activity of a fusion of esophageal carcinoma cells with dendritic cells derived from cord blood
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-15 / Cancer 2005 Aug;104(4):763-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-15 / Cancer 2005 Aug;104(4):763-702005-08-15 00:00:002019-02-15 08:35:31First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-01 / Oncol. Rep. 2005 Aug;14(2):353-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-01 / Oncol. Rep. 2005 Aug;14(2):353-62005-08-01 00:00:002019-02-15 08:36:23Prognostic significance of CD83 positive, mature dendritic cells in the gallbladder carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-01 / Clin. Cancer Res. 2005 Aug;11(15):5515-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-01 / Clin. Cancer Res. 2005 Aug;11(15):5515-252005-08-01 00:00:002019-02-15 08:46:55Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-01 / Int. J. Oncol. 2005 Aug;27(2):377-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-01 / Int. J. Oncol. 2005 Aug;27(2):377-842005-08-01 00:00:002020-06-23 09:37:35Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-01 / Br. J. Haematol. 2005 Aug;130(3):344-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-01 / Br. J. Haematol. 2005 Aug;130(3):344-622005-08-01 00:00:002019-02-15 09:25:43Immunotherapy in multiple myeloma–possibility or probability?
